Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 625,772 shares, an increase of 613.1% from the May 14th total of 87,758 shares. Based on an average daily trading volume, of 38,097,719 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.5% of the shares of the stock are sold short.

Institutional Investors Weigh In On Jupiter Neurosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the last quarter. Vestor Capital LLC boosted its stake in shares of Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the last quarter. Yorkville Advisors Global LP bought a new position in shares of Jupiter Neurosciences in the 4th quarter valued at about $135,000. Finally, Allen Capital Group LLC bought a new position in shares of Jupiter Neurosciences in the 4th quarter valued at about $31,000.

Jupiter Neurosciences Trading Up 1.8%

Shares of Jupiter Neurosciences stock traded up $0.00 during mid-day trading on Thursday, reaching $0.23. 2,035,704 shares of the stock were exchanged, compared to its average volume of 3,580,914. The company has a market cap of $8.31 million, a price-to-earnings ratio of -0.85 and a beta of 1.71. The firm has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.64. Jupiter Neurosciences has a fifty-two week low of $0.17 and a fifty-two week high of $3.33.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.23 million.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.